Failure of drugs and catheter ablation procedures for the treatment of ventricular arrhythmias (Vas) is still extremely relevant. Recently, stereotactic body radiotherapy has been introduced to treat therapy refractory patients. Conventional Vas ablation can be limited by incomplete (transmural) or difficult target accessibility with subsequent persistent arrhythmias or recurrence. Preclinical and clinical evidence on the efficacy and safety of Stereotactic radioablation (STAR) is limited qualitatively and quantitatively. The results of the only clinical prospective trials show that STAR is a promising treatment modality for a patient with therapy refractory VT. Recently STAR has been used a new promising treatment for atrial fibrillation in limited reports.
The aim of the Research Topic is to highlight the benefits and limitations of this new approach based on radiation oncologist and cardiologist’s point of view. We welcome Original Research as well as Case Report, Case series, Clinical Trial, Hypothesis and Theory, Methods, Perspective, Systematic Review.
Potential topics for the Research Topic include, but are not limited to:
1) Clinical inclusion criteria to STAR.
2) Pre-STAR treatment planning evaluation and of cardiac target volume definition: imaging tools for arrhythmia activation and substrate mapping and cardiac CT/MRI target delineation and merging.
3) STAR technical troubleshooting: total dose prescription, reference isodose prescription, cardiac volume and vulnerable intra and extracardiac structures, dose constraints, organ motion management, treatment delivery techniques, different delivery systems (Linac,
Cyberknife, Tomotherapy, MRguided Linacs; Proton-therapy and other solutions).
4) Clinical and Device Follow–up: time and modalities.
Failure of drugs and catheter ablation procedures for the treatment of ventricular arrhythmias (Vas) is still extremely relevant. Recently, stereotactic body radiotherapy has been introduced to treat therapy refractory patients. Conventional Vas ablation can be limited by incomplete (transmural) or difficult target accessibility with subsequent persistent arrhythmias or recurrence. Preclinical and clinical evidence on the efficacy and safety of Stereotactic radioablation (STAR) is limited qualitatively and quantitatively. The results of the only clinical prospective trials show that STAR is a promising treatment modality for a patient with therapy refractory VT. Recently STAR has been used a new promising treatment for atrial fibrillation in limited reports.
The aim of the Research Topic is to highlight the benefits and limitations of this new approach based on radiation oncologist and cardiologist’s point of view. We welcome Original Research as well as Case Report, Case series, Clinical Trial, Hypothesis and Theory, Methods, Perspective, Systematic Review.
Potential topics for the Research Topic include, but are not limited to:
1) Clinical inclusion criteria to STAR.
2) Pre-STAR treatment planning evaluation and of cardiac target volume definition: imaging tools for arrhythmia activation and substrate mapping and cardiac CT/MRI target delineation and merging.
3) STAR technical troubleshooting: total dose prescription, reference isodose prescription, cardiac volume and vulnerable intra and extracardiac structures, dose constraints, organ motion management, treatment delivery techniques, different delivery systems (Linac,
Cyberknife, Tomotherapy, MRguided Linacs; Proton-therapy and other solutions).
4) Clinical and Device Follow–up: time and modalities.
